Initial Safety Analysis of CapeOx for Elderly Patients With Advanced Gastric Cancer Patients: A Phase II Trial

• Main Authors: Chin, K. (Author), Goto, M. (Author), Hosaka, H. (Author), Ichikawa, W. (Author), Imamura, H. (Author), Ishizuka, N. (Author), Kawabata, R. (Author), Nagashima, F. (Author), Nakamura, M. (Author), Saitou, S.O (Author), Saotome, T. (Author), Shindo, Y. (Author), Shiraishi, T. (Author), Takahari, D. (Author), Yabusaki, H. (Author), Yamaguchi, K. (Author), Yamamoto, W. (Author)
• Format: Article
• Language: English
• Published: NLM (Medline) 2022
• Subjects: capecitabine; chemotherapy; elderly; Gastric cancer; oxaliplatin; phase 2 trial
• Online Access: View Fulltext in Publisher
• ISBN: 17917530 (ISSN)
• DOI: 10.21873/anticanres.15746

BACKGROUND: Safety of combination chemotherapy using platinum and fluorouracil has not been evaluated adequately for advanced gastric cancer (AGC) in elderly patients. PATIENTS AND METHODS: We initiated a phase II study to evaluate the efficacy and safety of capecitabine plus oxaliplatin (CapeOX) as first-line therapy for patients with AGC aged ≥70 years. Planned assessment of toxicity was made upon recruitment of the first 20 patients. RESULTS: In five out of 20 patients, unacceptable toxicity was observed, including three patients who were unable to complete the initial two courses due to adverse events. Among the other 15 patients, dose reduction due to toxicity were needed in 10 and treatment delay for adverse events also occurred in 12 patients during the first two courses. CONCLUSION: Early analyses of safety suggest that the CapeOX regimen was not tolerated without dose reduction for elderly patients with AGC in this study. Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.